WHEREAS, The Company has adopted a Laboratory Animal Care and Use policy (the "Policy") which appears on the Pfizer Website;¹

WHEREAS, the Policy asserts that Pfizer is committed to the “principles known as the 3Rs of animal research”;

WHEREAS, the 3Rs include i) the “refinement of the use of research animals to use less painful or the least invasive procedures whenever possible”; ii) the “reduction of the numbers of animals used in each study to the absolute minimum necessary to obtain valid results”; and iii) the “replacement of animal experiments with non-animal experiments such as mathematical models, computer simulations, and in vitro biological systems whenever appropriate”;

WHEREAS, it was reported in the Financial Times² that Pfizer and two other pharmaceutical companies³ donated four million pounds (£4M) to British universities to promote medical research and training specifically using animals;

WHEREAS, the article reported that Pfizer and the other two companies stated “the donation was part of a greater willingness by their industry to back animal testing publicly”;

WHEREAS, a credibility gap arises from the Company’s professed Policy and its affirmative promotion of animal testing as reported in the Financial Times;

RESOLVED, that the Board is requested to report to shareholders on the justification for affirmatively contributing to the advancement of animal-based testing while publicly promoting an animal care Policy that affirmatively commits to the advancement of non-animal based test methodologies.

SUPPORTING STATEMENT

Affirmatively supporting and promoting animal testing is wholly inconsistent with Pfizer’s Policy of reducing, refining, and replacing animal-based methods. Moreover, in the Proxy Materials for the 2004 annual meeting of shareholders, the Company relied on its commitment to the Policy in an effort to convince shareholders to vote against a Shareholder Proposal Relating to In Vitro Testing. That Proposal sought support for five validated non-animal test methods. The Company opposed the Proposal, arguing that Pfizer was fully committed to its animal care Policy which rendered the Proposal unnecessary. Pfizer made the following statements in the 2004 Proxy Statement:

• “We are committed to the principles embodied by the 3Rs of animal research: seeking alternatives that Reduce, Replace or Refine our work with animals when such alternatives are available and appropriate.”

• “Pfizer has always supported the use of in vitro alternatives ...”

• “We approach all research involving animals with the highest level of humane concern.”

• “[W]e are already working with regulators in an effort to increase the use of alternative models where such alternatives can be used appropriately.”

These statements cannot be reconciled with the decision to commit significant funds for the purpose of affirmatively promoting and publicly advancing animal testing and training graduate students to conduct animal experiments.

We urge our fellow shareholders to support this Resolution and bring Pfizer’s actions into harmony with the Company’s Animal Care and Use Policy.

¹ http://www.pfizer.com/pfizer/are/about_public /min_about_laboratory_use.jsp
² “Drugs groups to fund university animal research,” 7/29/04
³ The other two pharmaceutical companies are AstraZeneca and GlaxoSmithKline.

YOUR COMPANY’S RESPONSE

Pfizer remains committed to the use of alternative testing methods wherever such tests are scientifically valid and do not compromise patient safety or the effectiveness of our medicines. We are working with regulators in
an effort to increase the use of alternative models where such alternatives can be used appropriately. However, we are in agreement with regulators that the overall testing process must involve some level of *in vivo* testing in order to meet our overriding responsibility to provide patients with medicines that are both effective and as safe as possible.

It is in connection with this responsibility that Pfizer and the other pharmaceutical companies are working to support the quality of *in vivo* research in the UK. By providing these grants to institutions with expertise in the conduct of *in vivo* studies under the highest standards of animal welfare, we support training of a new generation of skilled scientists that will understand and apply the principles of humane care and use of research animals.

We believe that such funding is in complete harmony with those aspects of our Policy that relate to Respect for animals and Recognition of the important contributions that animal-based research makes to our goal of improving human and animal health worldwide, as well as seeking alternatives that Reduce, Replace or Refine our work with animals when such alternatives are available and appropriate.

The concerns of the proponent have been substantially addressed. The Board does not believe that adopting this proposal would be in the shareholders’ best interest.

**Your Board of Directors unanimously recommends a vote AGAINST this proposal.**